RESUMEN
AIM: To evaluate the clinical efficacy of P2Y2 agonist diquafosol sodium(DQS)eye drops in the treatment of diabetic dry eye.METHODS: A total of 80 patients(160 eyes)with diabetic dry eye who admitted to our hospital from January 2022 to March 2022 were selected. They were randomly divided into study group and control group. A total of 40 patients(80 eyes)in the study group were treated with 3% DQS eye drops and 40 patients(80 eyes)in the control group were treated with 0.3% sodium hyaluronate eye drops. The ocular surface disease index(OSDI)score, non-invasive tear meniscus height(NITMH), first non-invasive tear film break-up time(NIBUTf), average non-invasive tear film break-up time(NIBUTav), tarsal gland loss score, lipid layer thickness grade and bulbar redness analysis(including conjunctival grade and ciliary grade), were examined before treatment and at 1wk, 1 and 3mo after treatment, respectively. Furthermore, corneal fluorescence staining and conjunctival lissamine green staining were analyzed based on the ocular surface staining score(OSS), and the conjunctival impression cytology and confocal microscopy were evaluated before and 3mo after treatment, respectively.RESULTS: There were no differences in OSDI score, tarsal gland loss score, conjunctival grade score and ciliary grade score between the two groups before and after treatment(P>0.05). OSS scores in the study group were lower than those in the control group, while NITMH, NIBUTf and NIBUTav were higher than those in the control group at 1 and 3mo after treatment(P<0.05). After 3mo of treatment, the density of conjunctival goblet cells increased and corneal dendritic cells decreased in the study group compared with the baseline(all P<0.05), while there were no significant changes in the control group compared with the baseline(all P>0.05).CONCLUSION: 3% DQS eye drops were effective in treating diabetic dry eye without serious complications.
RESUMEN
Dry eye is a group of multifactor-induced ocular surface symptoms.The conventional therapy for dry eye is to increase the tear passively,such as topical administration of artificial tears eye drops and blockage of lacrimal punctum.However,with a better understanding of pathogenesis of dry eye,it is thought that an ideal method for dry eye is to promote the secretion of tear.Studies showed that P2Y2 receptor agonists can promote the lacrimal gland to secrete tear actively.Up to now,multiple synthetic P2Y2 receptor agonist mimics have been studied,and these studies confirmed that these drugs can improve the secretion of not only water-like tear but also mucoprotein,which can alleviate symptoms in patients with dry eye.In addition,good safety also is clarified by clinical trial of phase Ⅰ.This review briefly summarize the researches on active mechanism,clinical efficacy and applying prospect of P2Y2 receptor agonist for the treatment of dry eye.